Bank of America Corp /DE/ filed an amended Schedule 13G with the SEC on October 28, 2026, disclosing beneficial ownership of 357,318 shares of Inhibrx Biosciences, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Bank of America Corp /DE/ reported beneficial ownership of 357,318 shares of Inhibrx Biosciences, Inc. common stock.
  • Percent of class: The reported position represents 2.4% of the outstanding shares, based on 14,717,660 shares disclosed by the issuer on August 13, 2026.
  • Shared voting power: Bank of America reported shared voting power over 357,306 shares and zero sole voting power.
  • Shared dispositive power: Shared dispositive power covers 357,318 shares; sole dispositive power is reported as 0.00.
  • Filing event date: The triggering event date for this amended statement is September 30, 2026.
  • Subsidiaries covered: The filing covers positions held through BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, Merrill Lynch Pierce Fenner & Smith, Inc., and U.S. Trust Co of Delaware.

Bank of America's Disclosed Position in Inhibrx Biosciences as of September 30, 2026

According to the filing, Bank of America Corp /DE/, a Delaware-incorporated parent holding company headquartered at 100 N Tryon St, Charlotte, NC 28255, submitted this amended Schedule 13G in its capacity as a parent holding company or control person. The statement covers shares of common stock in Inhibrx Biosciences, Inc., a biosciences company whose principal executive offices are listed at 11025 N. Torrey Pines Road, Suite 140, La Jolla, California 92037. The CUSIP number for the reported security is 45720N103.

The filing discloses that the aggregate amount beneficially owned by Bank of America Corp /DE/ is 357,318 shares, representing 2.4% of the class. According to the filing, the beneficial ownership percentage calculation relies on the 14,717,660 outstanding shares disclosed in an issuer filing dated August 13, 2026, which reported share totals as of August 7, 2026. The filing notes that Bank of America holds zero sole voting power and zero sole dispositive power over the reported shares, with all voting and dispositive authority held on a shared basis across its subsidiaries.

The filing identifies the subsidiaries through which these holdings are held, including BofA Securities, Inc. and Merrill Lynch Pierce Fenner & Smith, Inc., both registered broker-dealers; Bank of America N.A., classified as a bank; Merrill Lynch International, classified as a non-U.S. institution; and U.S. Trust Co of Delaware, whose individual holding "does not exceed one percent of the reported securities," according to the filing. The statement was signed by Monica Yako as Authorized Signatory on October 28, 2026.

What Was Disclosed

Bank of America Corp /DE/ filed an amended Schedule 13G disclosing beneficial ownership of 357,318 shares, or 2.4%, of Inhibrx Biosciences, Inc. common stock as of September 30, 2026, held through multiple wholly owned subsidiaries with shared voting and dispositive power.